Recent News

• 09.15.2025 - Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
• 08.11.2025 - Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.05.2025 - Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Recent Filings

• 09.15.2025 - 8-K Current report
• 09.15.2025 - EX-99.1 EX-99.1
• 08.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.28.2025 - 144 Report of proposed sale of securities
• 08.28.2025 - 144 Report of proposed sale of securities
• 08.27.2025 - 144/A Report of proposed sale of securities
• 08.27.2025 - 144 Report of proposed sale of securities
• 08.27.2025 - 144 Report of proposed sale of securities
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]